Table 1.
Baseline characteristics in ischemic and non-ischemic patients
| Ischemic etiology (n = 11) | Non-ischemic etiology (n = 39) | p value | |
|---|---|---|---|
| Age (years)a | 61.5 ± 9.4 | 61.8 ± 10.9 | 0.920 |
| Male gender (%)a | 100.0 | 53.8 | 0.004 |
| Years since diagnosisa | 7.4 ± 5.3 | 5.8 ± 6.0 | 0.455 |
| NYHAa | 2.9 ± 0.3 | 3.1 ± 0.5 | 0.390 |
| HR (beats/min)a | 60.5 ± 7.4 | 72.8 ± 15.0 | 0.032 |
| QRS (ms)a | 130.0 ± 16.3 | 147.7 ± 31.1 | 0.093 |
| Diabetes (%) | 36.4 | 18.4 | 0.209 |
| CKD (%) | 10.0 | 19.4 | 0.497 |
| Hypertension (%) | 55.6 | 26.5 | 0.098 |
| Hyperlipidemia (%) | 80.0 | 40.0 | 0.026 |
| Statin (%) | 90.9 | 50.0 | 0.016 |
| Acetylsalicylic acid (%) | 72.7 | 21.9 | 0.002 |
| ACE-inhibitor (%) | 72.7 | 71.9 | 0.958 |
| AT-1 blocker (%) | 9.1 | 15.6 | 0.600 |
| Beta-blocker (%) | 90.9 | 87.5 | 0.768 |
| Spironolactone (%) | 45.5 | 65.6 | 0.248 |
| Furosemide (%) | 90.9 | 100.0 | 0.088 |
| Ivabradine (%) | 9.1 | 15.6 | 0.600 |
| Digoxin (%) | 36.4 | 34.4 | 0.908 |
| LVESV (mL)a | 157.7 ± 35.0 | 200.1 ± 98.5 | 0.193 |
| LVEDV (mL)a | 218.3 ± 37.9 | 250.1 ± 106.2 | 0.363 |
| LVEF (%)a | 26.5 ± 6.3 | 22.3 ± 6.8 | 0.078 |
| BNP (pg/mL)a | 381.1 ± 330.5 | 550.0 ± 602.5 | 0.458 |
| CRT-D versus CRT-P (%) | 100.0/0.0 | 81.3/18.8 | 0.308 |
aMean ± standard deviation
ACE angiotensin-converting enzyme, CKD chronic kidney disease, BNP brain natriuretic peptide, CRT-D cardiac resynchronization therapy-defibrillator, CRT-P cardiac resynchronization therapy-pacemaker, HR heart rate, LVEDV left ventricular end-diastolic volume, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, NYHA New York Heart Association